Glucagon-like peptide-1 (GLP-1) receptor agonists, initially developed for type 2 diabetes, have shown promise in managing GDM by improving glycemic control, enhancing insulin sensitivity, and assisting in weight management. This evidence concerns the gene INS and type 2 diabetes mellitus.